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OBJECTIVE—The adipocyte-derived secretory protein adi-
ponectin has been widely studied and shown to have potent
insulin-sensitizing, antiapoptotic, and anti-inﬂammatory proper-
ties. While its biosynthesis is well understood, its fate, once in
circulation, is less well established.
RESEARCH DESIGN AND METHODS—Here, we examine
the half-life of adiponectin in circulation by tracking ﬂuores-
cently labeled recombinant adiponectin in the circulation, fol-
lowing it to its ﬁnal destination in the hepatocyte.
RESULTS—Despite its abundant presence in plasma, adiponec-
tin is cleared rapidly with a half-life of 75 min. A more bioactive
version carrying a mutation at cysteine 39 is cleared within
minutes. Even though steady-state levels of adiponectin differ
between male and female mice, we failed to detect any differ-
ences in clearance rates, suggesting that differences in plasma
are mostly due to differential production rates. In a metabolically
challenged state (high-fat diet exposure or in an ob/ob back-
ground), adiponectin levels are reduced in plasma and clearance
is signiﬁcantly prolonged, reﬂecting a dramatic drop in adiponec-
tin production levels.
CONCLUSIONS—Combined, these results show a surprisingly
rapid turnover of adiponectin with multiple fat pads contributing
to the plasma levels of adiponectin and clearance mediated
primarily by the liver. It is surprising that despite high-level
production and rapid clearance, plasma levels of adiponectin
remain remarkably constant. Diabetes 58:1961–1970, 2009
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diponectin is a relatively abundant protein se-
creted from adipocytes circulating in the micro-
grams per milliliter range. It acutely lowers blood
glucose levels through suppression of hepatic
glucose levels and chronically has potent insulin-sensitizing
effects through reduction of hepatic lipids (1–3). Various
disease states are associated with lower plasma adiponectin
levels. Speciﬁcally, type 2 diabetic subjects and patients with
early-stage cardiovascular disease have lower levels of adi-
ponectin (4,5).
Adiponectin circulates in three different forms: high mo-
lecular weight (HMW) (18–36 mer), low molecular weight
(LMW) (hexamer), and a trimeric form. Levels of the HMW
form are tightly connected to insulin sensitivity (6). The
relevance of the hexameric and trimeric forms has not yet
been systematically addressed. Stable higher-order complex
formation requires the presence of disulﬁde bond formation
at position 39. Recombinant versions of adiponectin carrying
a conversion of cysteine 39 to an alanine display much more
potent glucose-lowering effects than wild-type protein (7).
This suggests that a reduction step at the level of the target
organ may play an important role in the activation of the
protein into a bioactive form. Direct evidence for such a step
is, however, lacking to date. The three monomers constitut-
ing the trimer form of adiponectin are held together via a
strong hydrophobic trimer interface in the globular head as
well as a highly dithiotreitol (DTT)-resistant intratrimer di-
sulﬁde bond. Hence, converting cysteine 39 to an alanine
results in predominantly trimeric isoforms, which differ from
the native trimer form by the intratrimer dilsuﬁde bond.
Once secreted, adiponectin may exert its effects through
binding to a set of receptors, such as the adipoR1 and
adipoR2 and/or T-Cadherin (8,9). Although activation of
AMP-activated kinases as well as peroxisome prolifera-
tors–activated receptor  are postulated to play a role in
mediating the adiponectin signal in liver and muscle, the
direct signaling pathways remain somewhat controversial.
In addition, the relevance of the adipoR1 and adipoR2 has
been questioned in several publications (10,11).
As with any protein in circulation, steady-state levels are
governed by the rate of release and the clearance rate of the
protein. Despite a wealth of data on transcriptional and
posttranslational regulation of adiponectin in the secretory
pathway, the clearance of adiponectin has not been studied.
Here, we take advantage of a dye-labeled, mammalian-pro-
duced recombinant adiponectin preparation that ﬂuoresces
in the near-infrared range and use these preparations to
follow the fate of adiponectin in vivo.
RESEARCH DESIGN AND METHODS
Mice (FVB) were maintained on a 12-h dark/light cycle and fed a normal diet.
All animals were 8–10 weeks old at the time of the experiments. For clearance
studies, wild-type FVB, adiponectin-null FVB, and FVB ob/ob mice were bred
in-house in our animal facility. Pregnant mice were used on day 18 after
conception. Characterization and description of the mice overexpressing
adiponectin from the liver is currently in progress (K.D. and P.E.S., unpub-
lished data). The high-fat diet consisted of 60 E% from fat (Research Diets,
New Brunswick, NJ). The institutional animal care and use committee of the
University of Texas Southwestern Medical Center and the Albert Einstein
College of Medicine approved all animal experimental protocols. The
IRDye800CW and 700CW infrared N-hydroxisuccinimide ester dyes were
purchased from Licor Biotechnology (Lincoln, NE). Protease inhibitor cock-
tail was obtained from Calbiochem. Sterile PBS was purchased from EMD
Chemicals.
Protein production and labeling. Wild-type and cysteine 39 adiponectin
were produced as previously described (7,12). To isolate HMW, LMW, and
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DIABETES, VOL. 58, SEPTEMBER 2009 1961trimer isoforms, recombinant adiponectin was separated by fast protein liquid
chromatography and 24 fractions were collected. Adiponectin levels in the
different fractions were then analyzed by Western blotting, and the fractions
containing the individual complexes were collected and concentrated to a
ﬁnal protein concentration of 1 mg/ml. Validation of the enrichment of the
different isoforms showed that we were able to isolate fractions highly
enriched in the various isoforms (Fig. 1D). Mouse IgGs were purchased from
Sigma Aldrich. Wild-type and cysteine 39 adiponectin, HMW, LMW, and trimer
were derivatized with the IRDye 800CW, and IgGs were labeled with IRDye
700CW at a dye:protein 1:1 molar ratio, according to the manufacturer’s
instructions.
Analysis for half-life determinations. The circulating half-life of adiponec-
tin was determined in the following settings: 8-week-old male and female FVB
mice, in females pregnant at day 18, in males fasted for 48 h, in 8-week-old
ob/ob male FVB mice, and in male FVB mice fed a high-fat diet for 6 weeks. In
addition, the circulating half-life of HMW, LMW, trimer, and cysteine 39
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FIG. 1. Adiponectin clearance. A: Upper panel shows the ﬂuorescent signal from the injected labeled adiponectin gel scan of 1.5 l serum
separated on SDS-PAGE over time. The lower panel shows the same gel after a Coomassie stain for loading control. Apn, Adiponectin; LC,
immunoglobulin light chain. B: Clearance curve for wild-type adiponectin in male and female FVB mice as well as native adiponectin and IgG. The
clearance of native adiponectin was determined by injecting wild-type serum into adiponectin-null mice. C: Clearance curves for male FVB mice
fed a normal as well as high-fat diet, male ob/ob FVB mice, and male FVB mice fasted 24 h. D: To isolate the three forms of adiponectin,
recombinant adiponectin containing all three forms (upper panel) were subjected to gel ﬁltration to create elutions containing the individual
isoforms. The lower panel shows a subsequent analysis of the complex distribution of the isolated fractions. E: The clearance curve of isolated
HMW, LMW, trimer, and cysteine 39 adiponectin in male FVB mice. F: The calculated half-life for wild-type adiponectin in male, female, pregnant
female, 24-h–fasted male, ob/ob mice, high-fat diet–fed mice, isolated HMW, isolated LMW, isolated trimer, and for the cysteine 39 adiponectin
in male mice. n  4 per group. *P < 0.05 vs. clearance rate of male wild-type FVB mice.
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1962 DIABETES, VOL. 58, SEPTEMBER 2009adiponectin were determined in 8-week-old male FVB mice. We and others
have previously determined adiponectin levels under these various conditions
in Combs et al. 2003 (13), Berg et al. 2001 (1), and Haluzik et al. 2004 (14). For
all conditions, the clearance was determined by injecting 0.05 g labeled
adiponectin/g body wt into the tail vein and by collecting blood samples at the
indicated time points in heparinized capillary tubes. A total of 1.5 l plasma
was subsequently mixed with 19 l TBS and 5 l5 Laemmli buffer. After
separation on a 10% Bis-Tris gel (Invitrogen, Carlsbad, CA), the labeled
proteins were directly visualized in the gel on the Licor Odyssey infrared
imaging system in the 700- and 800-nm channels, without any prior staining
techniques or transfers. Following scanning, the gel was stained with Com-
massie Blue stain, and the IgG light-chain band was quantiﬁed as loading
control. The 32-kDa adiponectin band obtained from the gel scans and the
25-kDa IgG light-chain band from the Coommassie stain were quantiﬁed with
Odyssey version 2.1 software.
In a ﬁnal set of experiments, the clearance of endogenous adiponectin was
studied by injecting 200 l serum from wild-type mice into 8-week-old
adiponectin-null mice. The levels of circulating adiponectin at the various time
points in the adiponectin-null mice were determined by enzyme-linked immu-
nosorbent assay (Millipore). The circulating half-life of adiponectin was
deﬁned as the time it took to remove 50% of the injected material from
circulation.
Analysis of mouse adiponectin complexes. Analysis of the adiponectin
complex distribution was performed as described in Schraw et al. (12) using
a rabbit polyclonal anti-mouse adiponectin primary antibody.
Scanning of mice in vivo. Prior to injection of the labeled material, chest and
abdominal hair was removed with Nair hair remover (Church & Dwight). All
scans were performed under anesthesia (Aerrane, Baxter, IL) using an EZ-2000
Microﬂex small-animal anesthesia system (EZ Systems, Palmer, PA). Once under
full anesthesia, the mice were transferred to an Odyssey Infrared Scanner (Li-Cor
Biosciences, Lincoln, NE) with an Odyssey mousePOD connected to the anes-
thesia apparatus. The full-body scans were performed with a resolution of 169
m, a focal plane lifted 4 mm, and the ﬂuorescence was measured in the 700- and
800-nm channels. Following the initial prescan, the labeled material was injected
into the tail vein. Wild-type and cysteine 39 adiponectin and IgGs were given at
0.05 g/g body wt in a total volume of 200 l. For the control experiments,
wild-type adiponectin was denatured and reduced by boiling for 15 min with the
presence of 1% SDS and 1 mmol/l DTT in a total volume of 50 l. At
the indicated time points, the mice were scanned and the liver signals were
quantiﬁed using the Odyssey version 2.1 software.
Organ analysis. To remove residual labeled material in the blood stream, the
mice were perfused (3.6 ml/min) with 20 ml PBS by entry into the left ventricle
and exit through the right atrium. The target organs were excised and scanned
on the Odyssey Infrared Scanner in the 800-nm channel. Following the scan,
tissues were snap frozen. To further process samples, they were homogenized
in TNET buffer (50 mmol/l Tris, pH 7.5; 150 mmol/l NaCl; 5 mmol/l EDTA; and
1% Triton X-100) with protease inhibitors and centrifuged at 14,000 rpm for 15
min at 4°C. The protein concentration of the supernatants was measured with
the bicinchoninic assay (Pierce), and 20 l were spotted directly on to a
nitrocellulose membrane. The signals on the membranes were directly quan-
tiﬁed (without any washing) with the Odyssey Infrared Scanner.
Microscopy and immunoﬂuorescence. To visualize exogenously adminis-
tered adiponectin, 8-week-old adiponectin-null mice were administered 0.5
g/g body wt wild-type and cysteine 39 adiponectin or PBS. After2ha n d
20 min, the mice were perfusion ﬁxed with 10% formalin. For detection of
endogenous adiponectin, 8-week-old adiponectin-null and wild-type mice
were perfusion ﬁxed in 10% formalin. In both experiments, the liver, kidney,
spleen, and gastrocnemius muscle were excised and processed for histology.
Tissue sections were decorated with an antibody targeting the NH2-terminal
region of adiponectin, anti-K8/18, and 4,6-diamidino-2-phenylindole. Fluores-
cence was detected using the Leica TCS SP5 confocal microscope. Images
were processed using ImageJ (Wayne Rasband, National Institutes of Health).
The same set of image processing steps was applied to both the control and
the experimental images.
Statistics. The results are shown as means  SE. All statistical analysis was
performed in SigmaStat 2.03 (SysStat Software, Point Richmont, CA). Differ-
ences in Fig. 1B were determined by the two-way ANOVA for repeated
measures. For comparison between two independent groups, the Student’s t
test was used. Signiﬁcance was as accepted at P  0.05.
RESULTS
Rapid clearance of adiponectin from circulation.
Adiponectin was recombinantly produced in 293-T cells
as previously described (15). This preparation was
subsequently derivatized with a N-hydroxisuccinimide–
IRDye 800CW such that each trimer was labeled with 1
dye molecule. The derivatized molecule retained its
multimeric conformation (online appendix Fig. 1 [avail-
able at http://diabetes.diabetesjournals.org/cgi/content/full/
db08-1750/DC1) and maintained its bioactivity as judged by
its ability to induce a glucose-lowering effect in vivo if
injected at 0.5 g/g body wt (data not shown). To deter-
mine the clearance rate for adiponectin during different
physiological as well as pathophysiological conditions, we
injected these preparations intravenously into mice and
frequently sampled plasma levels over the next 3 h. Figure
1A (upper panel) shows the ﬂuorescence derived from the
labeled adiponectin after separation on SDS-PAGE con-
taining plasma from mice injected with labeled adiponec-
tin. The lower panel shows the 25-kDa IgG light-chain
band of a subsequent Coommassie stain of the same gel,
serving as a loading control.
While females tend to have signiﬁcantly higher levels of
adiponectin in circulation, wild-type adiponectin clears
plasma with a rate of 75 min in both male and female
FVB mice (Fig. 1B and F). To validate that our labeled
recombinant adiponectin behaves similar to native adi-
ponectin in circulation, we injected 200 l serum from
wild-type mice into adiponectin-null mice and measured
clearance of adiponectin levels by enzyme-linked immu-
nosorbent assay over the next 3 h (Fig. 1B and F). No
differences could be observed between the endogenous
(“native”) adiponectin and the recombinant, puriﬁed
adiponectin.
Next, we wanted to know whether conditions charac-
terized by altered adiponectin levels also had differ-
ences in clearance rates. We have previously shown that
long-term fasting causes adiponectin levels to increase
signiﬁcantly. Comparing clearance rates between ad
libitum–fed mice and mice fasted for 24 h did not reveal
any differences at the level of clearance (Fig. 1C and F).
We have also shown that during pregnancy, adiponectin
levels drop signiﬁcantly, in line with the decreased
systemic insulin sensitivity in the mothers (16). How-
ever, clearance rates between female control mice and a
cohort of pregnant females did however not reveal any
differences, suggesting that a reduction of adiponectin
production is the major driving force behind the sys-
temic reduction (Fig. 1F). Even more striking is our
observation that the half-life of adiponectin is signiﬁ-
cantly extended in ob/ob mice or in wild-type mice
exposed to a high-fat diet compared with wild-type
controls fed a standard diet (Fig. 1E and F). The
decreased plasma levels found under these conditions
are therefore primarily due to the reduced production
rate in these animals.
The HMW form of adiponectin has been shown to
correlate better to insulin sensitivity than total levels
(6). We therefore wondered if the clearance of the
individual adiponectin complexes differed in regards to
clearance rate. The three isoforms were isolated by gel
ﬁltration of recombinant adiponectin and labeled at the
ratio of one dye per trimeric subunit (Fig. 1D and F).
Interestingly, the half-life did in fact diverge between
HMW, LMW, and the trimer isoform, such that HMW has
the slowest clearance (83.3  7 min), followed by LMW
(54.5  3.7 min) and trimer (32.4  1.2 min). Surpris-
ingly, the much more bioactive cysteine 39 mutant
protein cleared the system with a half-life of 10 min
(6.8  0.3 min).
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Preparations of the wild-type protein and the cysteine 39
mutant were injected intravenously into wild-type mice,
and the distribution of the labeled protein was followed
longitudinally in real time using a Licor Infrared detector
unit highly sensitive to emission wavelengths in the infra-
red range. Detection at these very long wavelengths has
the advantage that there are very low levels of autoﬂuo-
FIG. 2. Whole-body imaging of injected adiponectin. Visualization of injected labeled mammalian produced wild-type adiponectin (A), cysteine 39
adiponectin (B), and quenched IRDye800 without conjugation to protein by the Licor Infrared Scanner (C). Wild-type (WT) and cysteine 39
adiponectin were injected (0.05 g/g body wt) and the mice scanned 30 min, 1, 2, 3, 4, 5, 6, and 24 h postinjection. D: The liver signals from A and
B were quantiﬁed and plotted over time. *P < 0.05 between the wild-type and cysteine 39 protein. n  4 for each set of injections. E: SDS-PAGE
analysis of labeled adiponectin in the urin and in the plasma.
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associated with deeper penetration into the tissues com-
pared with wavelengths within the visible spectrum.
Upon injection, both the wild-type (Fig. 2A) and cysteine
39 mutant proteins (Fig. 2B) partition to the liver. In
contrast, the injection of quenched dye alone causes
clearance through the kidney and elimination from the
system through urine as judged by the bright appearance
of the bladder (Fig. 2C). In line with the differential
clearance rates, the cysteine 39 mutant accumulates with
considerably faster kinetics than wild-type protein. A
quantiﬁcation of the total signal in the liver and its changes
over time are shown in Fig. 2D. This highlights the fact that
the signal for the cysteine 39 mutant peaks as early as 30
min, whereas the signal for the wild-type protein takes up
t o4ht oaccumulate the highest signal intensity. Both
proteins seem to get degraded, and the ﬂuorescent label
can ultimately be found in the bladder as well. At this
stage, however, the protein is no longer full length, and
labeled adiponectin can only be detected as a broad
heterogeneous smear when urine samples are separated
on SDS-PAGE (Fig. 2E). Although the different kinetics of
liver signal between the wild-type and cysteine 39 adi-
ponectin are in it self highly suggestive of a speciﬁc signal
and not just a ﬂuid-phase uptake phenomenon, we per-
formed two additional control experiments. First, we
wanted to test the outcome if we disrupt the original
structure of the recombinant protein by boiling the prep-
aration in the presence of 1% SDS and 1 mmol/l DTT. Even
though some of this material may partially refold in vivo,
this preparation accumulated to a different extent and with
completely different kinetics in the liver and displayed a
clearance rate comparable to that of the cysteine 39
adiponectin (online appendix Figs. 2 and 5). In addition,
we wanted to compete the liver binding of labeled adi-
ponectin with increased levels of endogenous adiponectin.
For this purpose, we used a transgenic mouse model
engineered to express adiponectin from the liver under the
control of the transthyretin promoter. These mice have a
fourfold increase in circulating adiponectin compared
with wild-type mice (K.D., P.E.S., unpublished observa-
tions). Similar to the denatured material, the injected
adiponectin bound the liver with radically different kinet-
ics (online appendix Figs. 3 and 4). Importantly, in both
cases we set the maximal level to 100% to display the
kinetics of clearance in relative terms. It is difﬁcult to
assess the absolute levels of tissue accumulation between
different injections in quantitative terms, but the signal
intensity in the liver was distinctly lower with both dena-
tured adiponectin as well as in the overexpressing mice
relative to injection of native protein into wild-type mice.
Liver and kidney accumulate exogenously adminis-
tered adiponectin most efﬁciently. The detection of
labeled adiponectin in the intact animal offers the advan-
tage of monitoring the distribution of the protein in real
time. While powerful from a global perspective, this suffers
from the inherent disadvantage that some organs may
appear selectively more intense due to the closer proxim-
ity to the detection unit. To overcome this bias, organs
were excised upon injection of wild type (4 h) and cysteine
39 mutant (1.5 h) post injection. Organs were harvested
and protein lysates were prepared and quantiﬁed by
dot-blot analysis (Fig. 3A). As expected from the whole-
body images, the liver and kidneys are responsible for the
major adiponectin signal intensity. When the protein ly-
sates were separated on SDS-PAGE, the adiponectin could
only be visualized as a smear in all cases (data not shown),
indicating a rapid degradation once the molecule is taken
up inside the cell. Surprisingly, we also found a signiﬁcant
signal in the spleen, whereas we detected only very low
signal in gastrocnemius, heart, small intestine, colon,
pancreas, white adipose tissue, or testis. These observa-
tions were conﬁrmed by scanning whole organs directly
on the infrared scanner (Fig. 3B). Even though we saw a
relatively high intensity signal in spleen, we were unable to
demonstrate that this is a speciﬁc signal. Upon analysis of
the spleens from mice injected with boiled and reduced
adiponectin, we observed the same signal (data not
shown), suggesting that the signal in the spleen is unspe-
ciﬁc. Importantly however, even though the organs we
examined displayed relatively low or no speciﬁc signal
for adiponectin, we cannot rule out that a small subset
of cells within a given tissue bind and take up adiponec-
tin avidly. Our goal here is to determine whole-organ
FIG. 3. Adiponectin target organs. A: Dot-blot analysis of injected
wild-type (WT) adiponectin in different organ lysates 4 h postinjection.
Bar graph shows the signal intensity and below a representative dot
blot. B: Representative direct infrared scanning of the full organs 4 h
postinjection. Epi, epididymal white adipose tissue; Gast, gastrocne-
mius muscle; Kid, kidney; Liv, liver; Mes, mesenteric white adipose
tissue; Pan, pancreas; Sol, soleus muscle; SubQ, subcutaneous white
adipose tissue. n  4.
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DIABETES, VOL. 58, SEPTEMBER 2009 1965contribution to clearance. Low levels of signal in an
organ should not be taken to rule out uptake of adi-
ponectin by a small subset of cells, rather it indicates
that a particular tissue is not a major contributor to
clearance as a whole.
Clearance of the adiponectin signal at the cellular
level. Given the high intensity of signal in the liver, we
wondered whether we could develop an imaging method
that would enable us to monitor the uptake of injected
adiponectin into hepatocytes. To that end, we injected
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FIG. 4. Visualization of exogenously administered adiponectin in the liver and kidney. A: Wild-type (WT) and cysteine 39 adiponectin were injected
(0.5 g/g body wt) into adiponectin-null mice and the liver processed for histology. The exogenous adiponectin was next visualized in the liver using
an antiadiponectin antibody 20 min and 2 h postintravenous injections. As a control, PBS was injected without any adiponectin. K8/18 was used as an
endothelial marker, and DAPI was used to visualize the nuclei. B: Adiponectin and DAPI stain in the kidney 20 min and 2 h after intravenous injection
of adiponectin into adiponectin-null mice. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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body wt) intravenously into adiponectin-null mice and
sampled livers at 20 min and 2 h. In line with the more
rapid kinetics of the cysteine 39 mutation, the adiponectin
signal in the hepatocyte was prevalent at the early 20-min
time point, whereas the wild-type adiponectin signal at
this stage was located in the surrounding microvessels as
evident by a colocalization with K8/18 (Fig. 4A). Two
hours after injection, adiponectin can be seen intracellu-
larly in the hepatocytes for both wild-type and cysteine 39
adiponectin (Fig. 4A). As these images were obtained by
immunoﬂuorescence, we do not known whether the signal
arises from full-length or degraded adiponectin. As for
kidney, wild-type adiponectin could only be detected
weakly in the kidney sections 20 min after injection,
whereas the more active cysteine 39–mutated adiponectin
was abundantly apparent intracellularly at this time point
as well. After 2 h, the cysteine 39 signal in the kidney was
already markedly decreased as suspected by the short
half-life. Levels of wild-type adiponectin, however, were
increased compared with 20 min (Fig. 4B). Notably, the
adiponectin detected in the kidney is mostly in the tubules
with more limited signal in the glomeruli and appears to be
mostly intracellular. No signal could be detected in the
spleen or in gastrocnemius muscle (data not shown). The
lack of signal in the spleen conﬁrms the nonspeciﬁc
nature of the signal in this tissue, as discussed above.
Endogenous adiponectin. To further validate that the
exogenous material behaved comparably to endogenous
adiponectin, we visualized endogenous adiponectin in
liver sections from wild-type and adiponectin-null mice.
This, of course, represents a steady-state level of adi-
ponectin as compared with the bolus injection described
above. As seen for the exogenous adiponectin, endoge-
nous adiponectin can be located to larger vessels in the
liver (Fig. 5A), which is in accordance with previously
published data (17). In addition, we were able to detect
adiponectin surrounding the individual hepatocytes with a
distinct plasma membrane stain (Fig. 5A). Intracellular
adiponectin was also detected, although at much lower
frequency and much weaker than that observed with
injected adiponectin, conﬁrming that in the steady-state
adiponectin (or at least the epitope that we use for
visualization with our antibodies) is degraded rapidly. As
with the liver, we were able to detect adiponectin signal in
the blood vessels of the kidney (Fig. 5B). However, we did
not reproducibly pick up intracellular signal. Interestingly,
when we probed the gastrocnemius muscle for endoge-
nous adiponectin, we detected a sarcolemal signal (Fig.
5B). This was not seen with the exogenous adiponectin.
There is still only weak evidence available arguing for an
in vivo action of adiponectin on muscle. It remains unclear
whether adiponectin plays a physiological role in muscle
and what the sarcolemmal signal indicates.
DISCUSSION
To our knowledge, this is the ﬁrst study that addresses the
in vivo fate of adiponectin and determines its half-life in
circulation under both physiological and pathophysiologi-
cal conditions. We have found that adiponectin circulates
with a half-life of 75 min. This clearance state is rela-
tively stable and shows no difference between the sexes,
with long-term fasting, or during pregnancy (all situations
known to alter the circulating levels of adiponectin). That
said, however, both genetically (ob/ob mice) and diet-
C39 Adiponectin 2 hrs C39 Adiponectin 20 min
WT Adiponectin 2 hrs WT Adiponectin 20 min
B
PBS
FIG. 4. Continued.
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adiponectin. Thus, the lower adiponectin levels observed
under these conditions must be a result of diminished
secretion rather than an increased clearance.
At this stage, there is very limited evidence to whether
the three different adiponectin complexes have similar
functions or work in concert with each other. The fact that
HMW adiponectin levels are more tightly correlated with
insulin sensitivity than total adiponectin suggests that
there might be differences. Here, we show that HMW,
LMW, and trimer adiponectin are cleared differentially, in
such that HMW is cleared slowest (T1/2 85 min) and
trimer fastest (T1/2 32 min). At this stage, we can only
speculate as to why the HMW form is cleared more slowly
than the other two isoforms. The HMW form may serve as
a storage compartment for trimeric subunits that get
locally generated upon reduction of the HMW form. Alter-
natively, exit of the HMW form from circulation may be
slowed down due to its size. The time in circulation for
trimeric adiponectin can be even further reduced to 10 min
by mutating cysteine 39 to alanine. We do not believe that
this shortened half-life is a reﬂection of an unfolded or
generally unstable recombinant protein for several rea-
sons. First, this recombinant protein is highly bioactive.
Second, we have generated transgenic mice that overex-
press this mutant in adipocytes. While the synthesis and
release of this protein occurs at levels comparable to
wild-type protein, the steady-state levels of the mutant are
1% of wild-type levels, consistent with a very short
half-life of this protein in circulation (K.D., T.S., P.E.S.,
unpublished observations). The cysteine 39 mutant adi-
ponectin is physiologically more active as determined by
its ability to lower glucose. This implies that the intratri-
mer disulﬁde bond (the only difference between wild-type
trimer and cysteine 39 mutant) plays a key role. The
intratrimeric disulphide bond may maintain the wild-type
protein in a “spring-loaded” conﬁguration that conveys a
conformational change throughout the protein upon
reduction.
It is interesting to note that the potently bioactive
cysteine 39 mutant is also the form with the fastest
clearance. Combined with the delayed clearance of adi-
ponectin in the high-fat diet and ob/ob models, this sug-
gests that rapid clearance goes hand in hand with high
bioavailability and activity, whereas delayed clearance is
an indicator of metabolic dysfunction. Importantly, how-
ever, these are only correlations, and we are focusing here
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FIG. 5. Visualization of endogenous adiponectin in liver, kidney,
and muscle. A: K8/18 (endothelial marker), adiponectin, and DAPI
stain of 8-week-old wild-type (WT) and adiponectin-null livers. B:
Adiponectin and DAPI stain of kidney and gastrocnemius muscle
from wild-type and adiponectin-null mice. Yellow arrows show
large blood vessels. (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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equates bioactivity under all circumstances.
These differential effects on clearance of adiponectin
raise the important question as to how the clearance of
this protein is mediated. This remains a vastly unexplored
area. Like adiponectin, insulin has a profound effect on the
liver. After binding to the insulin receptor on the hepato-
cyte, the receptor-protein complex gets internalized into
the endosome where the insulin-degrading enzyme breaks
down the insulin (18). While insulin has a much shorter
half-life than adiponectin, it may be possible that adi-
ponectin (similar to insulin) is extracted every time it
passes through the liver. The detection methods used to
date are not sensitive enough to measure a gradient across
the splanchnic bed, but a combination of more robust
assays coupled with a focus on the measurement of the
different complexes individually may enable us to measure
such a gradient in the future.
Our histological analysis of both acutely administered
exogenous adiponectin as well as steady-state endogenous
levels have revealed several interesting observations. In all
the organs investigated, adiponectin can be visualized in
larger blood vessels. This is especially the case for visual-
ization of endogenous adiponectin whose steady-state
distribution is a reﬂection of adiponectin at various stages
of degradation. In contrast, our pulsed administration of
recombinant adiponectin allows us to follow a much more
homogenous population. The staining of the vessels is
consistent with a possible role of the adiponectin-binding
protein T-cadherin (8). The lack of an intracellular signal-
ing motif makes this protein an unlikely candidate as a
signal transducer. Instead, T-cadherin may function to
tether adiponectin to the vessel wall where a possible
reductase may cleave the full-length adiponectin into the
trimer. Accessibility to the hepatocytes is increased with
the cysteine 39 mutant, suggesting that this 90-kDa com-
plex may have more efﬁcient access across the endothe-
lium and the sinusoidal fenestrae as opposed to the
wild-type protein that can be as big as 500 kDa to 1
megadalton. We have not addressed the question whether
the published adiponectin receptors adipoR1 and adipoR2
are critically involved in this process.
It is also interesting to note that we detect a signiﬁ-
cant amount of signal in the kidney where it is primarily
in the tubules. Whether clearance in the kidney is a
phenomenon that is also relevant for native adiponectin
or whether it is a secondary site that clears a liver-
derived degradation product is not clear. However, an
important role of the kidneys for adiponectin levels has
been reported in several cases in patients with chronic
kidney disease (19).
It remains intriguing that an abundant plasma protein
such as adiponectin is cleared at such a rapid rate. This
results in a very high biosynthetic rate in the adipocytes.
Despite a high level of production and rapid clearance, it is
surprising that the steady-state levels in circulation are
remarkably stable and ﬂuctuate with minimal diurnal
variability. This implies that a communication axis be-
tween the different adipocytes, as well as among the
different adipose pads, must be strictly maintained. Fur-
thermore, plasma adiponectin is extremely stable, since it
can be stored for 36 h without any signiﬁcant losses due to
degradation, suggesting that clearance-based mechanisms
are the predominant method of elimination rather than
degradation in plasma (20).
In summary, we have shown here for the ﬁrst time the
clearance rate for the key metabolic hormone adiponec-
tin. We have furthermore shown that the clearance
varies for the different isoforms of adiponectin, with
HMW being cleared the slowest and the trimer the
fastest. Finally, we demonstrate that the liver is the
main site of clearance and the kidney only excretes ﬁnal
degradation products.
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